-continued

```
        595                 600                 605

Ser Thr Asp Asp Ile Trp Gly Asn Leu Thr Trp Gln Gln Trp Asp Lys
    610                 615                 620

Leu Val Ser Asn Tyr Thr Gly Lys Ile Phe Gly Leu Leu Glu Glu Ala
625                 630                 635                 640

Gln Ser Gln Gln Glu Lys Asn Glu Arg Asp Leu Leu Glu Leu Asp Gln
                645                 650                 655

Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Lys Trp Leu Trp Tyr
            660                 665                 670

Ile Lys Ile Phe Leu Met Ala Val Gly Gly Ile Ile Gly Leu Arg Ile
        675                 680                 685

Ile Met Thr Val Phe Ser Val Val Arg Arg Val Arg Gln Gly Tyr Ser
    690                 695                 700

Pro Leu Ser Leu Gln Thr Leu Ile Pro Val Gln Arg Glu Gln Gly Arg
705                 710                 715                 720

Leu Gly Glu Ile Asp Glu Gly Gly Gly Glu Gln Asp Arg Ser Arg Ser
                725                 730                 735

Val Arg Leu Val Glu Gly Cys Leu Pro Leu Ile Trp Asp Asp Leu Arg
            740                 745                 750

Asn Leu Gly Ile Trp Ser Tyr Gln Ser Leu Thr Ser Leu Ala Cys Asn
        755                 760                 765

Val Trp Arg Gln Leu Lys Thr Leu Gly His Leu Ile Leu His Ser Leu
    770                 775                 780

Arg Leu Leu Arg Glu Arg Leu Cys Leu Leu Gly Gly Ile Ile Gln Tyr
785                 790                 795                 800

Trp Gly Lys Glu Leu Lys Ile Ser Ala Ile Ser Leu Leu Asp Ala Thr
                805                 810                 815

Ala Ile Ala Val Ala Glu Gly Thr Asp Arg Ile Ile Glu Ala Phe Gln
            820                 825                 830

Val Thr Leu Arg Ile Ile Arg Asn Ile Pro Arg Arg Ile Arg Gln Gly
        835                 840                 845

Leu Glu Arg Ala Leu Leu
    850
```

1. An engineered or non-naturally occurring molecule from Simian Immunodeficiency Virus (SIV) that binds to a Human Immunodeficiency Virus (HIV) broadly neutralizing antibody (bnAb), in particular the V2 apex region of HIV envelope, or an engineered or non-naturally occurring molecule from SIV that binds to a germline or germline reverted HIV broadly neutralizing antibody (bnAb) directed to the V2 apex region of HIV envelope.

2.-**3**. (canceled)

4. The engineered or non-naturally occurring molecule of claim **1**,

wherein the HIV bnAb comprises one or more complementarity determining regions (CDRs) of a heavy chain variable domain of Table 2, and/or one or more CDRs of a light chain variable domain of Table 2, in particular wherein the HIV bnAB comprises an amino acid sequence at least 50% identical, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to PG9 or to CH01, or

which comprises a complex of gp120 and gp41, or variants thereof or

which comprises a stabilized trimer, in particular wherein the trimer is a SOSIP, NFL, or UFO trimer or

which comprises a V2 apex epitope of Simian Immunodeficiency Virus (SIV) or

wherein the SIV comprises SIVcpzPtt, SIVcpzPts, or SIVgor or

wherein the Env sequence of the SIV is from the SIVcpzPtt isolate MT145 or

wherein an immunodominant epitope is modified by deletion or substitution, in particular wherein amino acids of the V5 loop are substituted or deleted or

which comprises basic amino acid substitutions, in particular which comprises Lys at position 171 or

wherein the V2 apex region comprises two glycans and four consecutive basic amino acids.

5.-**16**. (canceled)